u-plex assay (meso scale multi-array Search Results


u-plex assay meso scale multiarray  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC u-plex assay meso scale multiarray
U Plex Assay Meso Scale Multiarray, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u-plex+assay+%28meso+scale+multi-array/pm37467721-136-1-3?v=Meso+Scale+Diagnostics+LLC
Average 90 stars, based on 1 article reviews
u-plex assay meso scale multiarray - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
multi-plex cytokine array u-plex  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC multi-plex cytokine array u-plex
Mammary tumors increase splenic bacterial burden and alter splenic cytokines. Tumor mice exhibit splenomegaly that is attenuated in Resected ( A ). Tumor mice also have increased splenic bacterial burden as detected by FISH ( B ). Tumor mice also have altered splenic <t>cytokine</t> profiles ( C ). Control, Tumor, and Resected mice do not differ in the number of animals with culture-positive spleens (60, 66.7, and 66.7% respectively,chi-square likelihood ratio p = 0.96), but Tumor mice tend to have less Lactobacillus -positive spleens ( D ). * = p < 0.05, ** = p < 0.01, *** = p < 0.0001, NS=Not Significant, ND=Not Detected, by ANOVA and post-hoc LSD
Multi Plex Cytokine Array U Plex, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u-plex+assay+%28meso+scale+multi-array/pmc08897840-107-14-18?v=Meso+Scale+Diagnostics+LLC
Average 90 stars, based on 1 article reviews
multi-plex cytokine array u-plex - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
multi-array elisa u-plex detection plates  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC multi-array elisa u-plex detection plates
Mammary tumors increase splenic bacterial burden and alter splenic cytokines. Tumor mice exhibit splenomegaly that is attenuated in Resected ( A ). Tumor mice also have increased splenic bacterial burden as detected by FISH ( B ). Tumor mice also have altered splenic <t>cytokine</t> profiles ( C ). Control, Tumor, and Resected mice do not differ in the number of animals with culture-positive spleens (60, 66.7, and 66.7% respectively,chi-square likelihood ratio p = 0.96), but Tumor mice tend to have less Lactobacillus -positive spleens ( D ). * = p < 0.05, ** = p < 0.01, *** = p < 0.0001, NS=Not Significant, ND=Not Detected, by ANOVA and post-hoc LSD
Multi Array Elisa U Plex Detection Plates, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u-plex+assay+%28meso+scale+multi-array/pmc07945035-85-3-25?v=Meso+Scale+Diagnostics+LLC
Average 90 stars, based on 1 article reviews
multi-array elisa u-plex detection plates - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Mammary tumors increase splenic bacterial burden and alter splenic cytokines. Tumor mice exhibit splenomegaly that is attenuated in Resected ( A ). Tumor mice also have increased splenic bacterial burden as detected by FISH ( B ). Tumor mice also have altered splenic cytokine profiles ( C ). Control, Tumor, and Resected mice do not differ in the number of animals with culture-positive spleens (60, 66.7, and 66.7% respectively,chi-square likelihood ratio p = 0.96), but Tumor mice tend to have less Lactobacillus -positive spleens ( D ). * = p < 0.05, ** = p < 0.01, *** = p < 0.0001, NS=Not Significant, ND=Not Detected, by ANOVA and post-hoc LSD

Journal: BMC Cancer

Article Title: Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation

doi: 10.1186/s12885-022-09274-0

Figure Lengend Snippet: Mammary tumors increase splenic bacterial burden and alter splenic cytokines. Tumor mice exhibit splenomegaly that is attenuated in Resected ( A ). Tumor mice also have increased splenic bacterial burden as detected by FISH ( B ). Tumor mice also have altered splenic cytokine profiles ( C ). Control, Tumor, and Resected mice do not differ in the number of animals with culture-positive spleens (60, 66.7, and 66.7% respectively,chi-square likelihood ratio p = 0.96), but Tumor mice tend to have less Lactobacillus -positive spleens ( D ). * = p < 0.05, ** = p < 0.01, *** = p < 0.0001, NS=Not Significant, ND=Not Detected, by ANOVA and post-hoc LSD

Article Snippet: The concentration of IL-10, IL-1β, IL-6, CXCL1, MCP-1, and TNFα were measured using a multi-plex cytokine array (U-Plex, MesoScale Discovery) according to manufacture protocol.

Techniques: Control

Working paradigm - Tumor-induced intestinal barrier disruption is permissive of enteric bacterial translocation. Tumors induce intestinal barrier disruption and decrease relative abundance of Lactobacillus through yet unknown mechanisms. Reduced abundance of Lactobacillus and barrier disruption allow higher enteric bacterial translocation to systemic sights including the spleen, where pro-inflammatory cytokine TNFα is reduced. These changes in intestinal physiology and immune function likely contribute to gastrointestinal and behavioral symptoms experienced by patients with cancer

Journal: BMC Cancer

Article Title: Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation

doi: 10.1186/s12885-022-09274-0

Figure Lengend Snippet: Working paradigm - Tumor-induced intestinal barrier disruption is permissive of enteric bacterial translocation. Tumors induce intestinal barrier disruption and decrease relative abundance of Lactobacillus through yet unknown mechanisms. Reduced abundance of Lactobacillus and barrier disruption allow higher enteric bacterial translocation to systemic sights including the spleen, where pro-inflammatory cytokine TNFα is reduced. These changes in intestinal physiology and immune function likely contribute to gastrointestinal and behavioral symptoms experienced by patients with cancer

Article Snippet: The concentration of IL-10, IL-1β, IL-6, CXCL1, MCP-1, and TNFα were measured using a multi-plex cytokine array (U-Plex, MesoScale Discovery) according to manufacture protocol.

Techniques: Disruption, Translocation Assay